Turner Syndrome Market is segmented By Therapy Type (Growth Hormone Therapy, Estrogen Replacement Therapy, Other Therapies), By Treatment Type (Pharma....
Market Size in USD
CAGR8.2%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 8.2% |
Market Concentration | High |
Major Players | Eli Lilly and Company, Novo Nordisk, Pfizer, Merck KGaA, Ascendis Pharma |
The Global Turner Syndrome Market is estimated to be valued at USD 1.21 billion in 2024 and is expected to reach USD 2.57 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031. This growth can be attributed to rising diagnosis rates and improvements in treatment therapies.
The Turner Syndrome market has been witnessing positive trends over the past few years. With increased awareness about women's health issues, more women are opting to get screened and diagnosed. Advancements in genetic testing technologies have made diagnosis more precise and less invasive. Research into understanding the genetic basis of the condition is also helping develop more effective long-term medical management solutions. Several clinical trials are ongoing to evaluate new lines of treatment that could further propel market revenues.